Loss of Attention May Suggest Faster Progression to Dementia in Very Early LBD

Like other dementias, a person doesn’t develop Lewy body dementia (LBD) overnight. Very mild symptoms worsen over time until medical attention is needed. Sometimes several years pass before these earliest […]
Read More

Biogen’s Aducanumab Clinical Trial Results Revealed

In a stunning reversal last October, pharma giant Biogen announced that its failed Phase 3 clinical trial of aducanemab in people with mild cognitive impairment or mild Alzheimer’s disease didn’t […]
Read More

Positive Results for the HARMONY Clinical Trial of Pimavanserin in Dementia-Related Psychosis

In December ACADIA Pharmaceuticals presented its top-line results from its Phase 3 clinical trial of pimavanserin in people who had dementia-related psychosis. The results had been eagerly awaited; ACADIA stopped […]
Read More

LBDA’s Contributions to the Scientific Community

Throughout the year, LBDA staff have been traveling across the country to promote discussion and awareness of Lewy body dementias in local communities and at national conferences. Here are just a […]
Read More

LBD Caregiver Experience Differs Between Spouses and Adult Children

Being a dementia caregiver can have a negative impact on one’s psychological well-being. But what is specifically known about the impact of LBD caregiving? And how it might differ based […]
Read More

Updated LBD Research Recommendations Published

Every 3 years, a national research summit is held to update research strategies for non-Alzheimer’s dementias. This 2-day national event is one of 3 rotating summits held in response to […]
Read More

National Institutes of Health Award $14 million for LBD Research

People who have LBD plus changes in the brain associated with Alzheimer’s disease tend to have more aggressive disease progression. However, science has not yet explained why these two disease […]
Read More

Rate of Dementia Diagnosis Varies by Clinician Type and Patient Race/Ethnicity

With an aging population and life expectancies on the rise, the number of people with dementia in the U.S. is projected to reach nearly 12 million in 20 years. However, […]
Read More

Treatment Study Halted Early Because of Promising Results

With all the recent news about failed clinical trials for disease-modifying treatments for Alzheimer’s disease, a little encouraging news is timely. ACADIA Pharmaceuticals announced an early end to one of […]
Read More

LBD is the Most Expensive Dementia in America

Dementia is one of the most expensive diseases in the United States, increasing healthcare costs 3 times over those without dementia. Until now, studies on the costs of different dementia […]
Read More